Cytokinetics Inc (NASDAQ: CYTK) is -36.99% lower on its value in year-to-date trading and has touched a low of $25.98 and a high of $110.25 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CYTK stock was last observed hovering at around $52.60 in the last trading session, with the day’s gains setting it 0.01%.
Currently trading at $52.61, the stock is -2.99% and -5.41% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.9 million and changing 0.02% at the moment leaves the stock -17.20% off its SMA200. CYTK registered 88.70% gain for a year compared to 6-month loss of -25.82%. The firm has a 50-day simple moving average (SMA 50) of $55.5228 and a 200-day simple moving average (SMA200) of $63.61545.
The stock witnessed a -3.57% gain in the last 1 month and extending the period to 3 months gives it a -3.29%, and is -0.13% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.02% over the week and 4.04% over the month.
Cytokinetics Inc (CYTK) has around 423 employees, a market worth around $6.19B and $3.13M in sales. Profit margin for the company is -17398.82%. Distance from 52-week low is 102.50% and -52.28% from its 52-week high. The company has generated returns on investments over the last 12 months (-62.77%).
The EPS is expected to grow by 6.02% this year
469.0 institutions hold shares in Cytokinetics Inc (CYTK), with institutional investors hold 118.44% of the company’s shares. The shares outstanding are 117.66M, and float is at 113.74M with Short Float at 15.69%. Institutions hold 117.84% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 14.67 million shares valued at $794.97 million. The investor’s holdings represent 14.3958 of the CYTK Shares outstanding. As of 2024-06-30, the second largest holder is FMR LLC with 11.52 million shares valued at $624.32 million to account for 11.3056 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 11.44 million shares representing 11.2218 and valued at over $619.69 million, while T. ROWE PRICE INVESTMENT MANAGEMENT, INC. holds 7.985 of the shares totaling 8.14 million with a market value of $440.95 million.
Cytokinetics Inc (CYTK) Insider Activity
The most recent transaction is an insider sale by Malik Fady Ibraham, the company’s EVP Research & Development. SEC filings show that Malik Fady Ibraham sold 7,300 shares of the company’s common stock on Oct 01 ’24 at a price of $52.10 per share for a total of $0.38 million. Following the sale, the insider now owns 0.12 million shares.
Still, SEC filings show that on Sep 30 ’24, Blum Robert I (President & CEO) disposed off 5,000 shares at an average price of $52.14 for $0.26 million. The insider now directly holds 397,456 shares of Cytokinetics Inc (CYTK).
